New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial

NCT ID NCT02213926

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning everyone gets the drug and researchers are checking for safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Locations

Research Site

Tampa, Florida, 33612, United States
Research Site

Chicago, Illinois, 60612, United States
Research Site

Niles, Illinois, 60714, United States
Research Site

Peoria, Illinois, 61615, United States
Research Site

Boston, Massachusetts, 2215, United States
Research Site

Hackensack, New Jersey, 07601, United States
Research Site

New York, New York, 10021, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Monash, Australia
Research Site

Sydney, 2139, Australia
Research Site

Wodonga, 3690, Australia
Research Site

Bruges, 8000, Belgium
Research Site

Brussels, 1000, Belgium
Research Site

Brussels, 1200, Belgium
Research Site

Liège, 4000, Belgium
Research Site

Yvoir, 5530, Belgium
Research Site

Prague, 100 34, CZ, Czechia
Research Site

Angers, 49033, France
Research Site

Caen, 14033, France
Research Site

Clermond Ferrand, 63003, France
Research Site

Créteil, 94010, France
Research Site

Dijon, 21000, France
Research Site

Grenoble, 38043, France
Research Site

La Roche - Sure-Yon, 85925, France
Research Site

Lille, 59000, France
Research Site

Montpellier, 34295, France
Research Site

Nantes, 44093, France
Research Site

Paris, 75015, France
Research Site

Paris, 75651, France
Research Site

Pessac, 33604, France
Research Site

Pierre-Bénite, 69310, France
Research Site

Rennes, 35033, France
Research Site

Rouen, 76038, France
Research Site

Saint-Priest-en-Jarez, 42270, France
Research Site

Strasbourg, 67098, France
Research Site

Toulouse, 31100, France
Research Site

Tours, 37000, France
Research Site

Vandœuvre-lès-Nancy, 54500, France
Research Site

Bologna, 40138, Italy
Research Site

Meldola, 47014, Italy
Research Site

Milan, 20132, Italy
Research Site

Novara, 28100, Italy
Research Site

Amsterdam, 1105 AZ, Netherlands
Research Site

Maastricht, 6202 AZ, Netherlands
Research Site

Rotterdam, 3062 PA, Netherlands
Research Site

Krakow, 30-727, Poland
Research Site

Lodz, 93-510, Poland
Research Site

Olsztyn, 10-228, Poland
Research Site

Badalona, 8916, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Cardiff, CF14 4XW, United Kingdom
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

Leicester, LE1 7RH, United Kingdom
Research Site

Nottingham, NG5 1PB, United Kingdom
Research Site

Oxford, 0X3 7LE, United Kingdom
Research Site

Plymouth, PL6 8DH, United Kingdom
Research Site

Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.